|
注册号: Registration number: |
ChiCTR2000038101 |
|
最近更新日期: Date of Last Refreshed on: |
2020-11-23 10:43:53 |
|
注册时间: Date of Registration: |
2020-09-10 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于移动健康技术的社区脑卒中预防控制综合干预研究 |
|
Public title: |
Study on integrated intervention for community-based stroke prevention and control with mobile health technology |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于移动健康技术的社区脑卒中预防控制综合干预研究 |
|
Scientific title: |
Study on integrated intervention for community-based stroke prevention and control with mobile health technology |
|
研究课题代号(代码): Study subject ID: |
81872721 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张伟伟 |
研究负责人: |
刘世炜 |
|
Applicant: |
Zhang Weiwei |
Study leader: |
Liu Shiwei |
|
申请注册联系人电话: Applicant telephone: |
+86 10-83136481 |
研究负责人电话:
Study leader's |
+86 10-83136483 |
|
申请注册联系人传真 : Applicant Fax: |
+86 10-63042350 |
研究负责人传真: Study leader's fax: |
+86 10-63042350 |
|
申请注册联系人电子邮件: Applicant E-mail: |
wwzhang86@163.com |
研究负责人电子邮件: Study leader's E-mail: |
shiwei_liu@aliyun.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市西城区南纬路27号 |
研究负责人通讯地址: |
北京市西城区南纬路27号 |
|
Applicant address: |
27 Nanwei Road, Xicheng District, Beijing, China |
Study leader's address: |
27 Nanwei Road, Xicheng District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
100050 |
研究负责人邮政编码: Study leader's postcode: |
100050 |
|
申请人所在单位: |
中国疾病预防控制中心慢性非传染性疾病预防控制中心 |
||
|
Applicant's institution: |
National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention |
||
|
研究负责人所在单位: |
中国疾病预防控制中心慢性非传染性疾病预防控制中心 |
||
|
Affiliation of the Leader: |
National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
202005 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国疾控中心伦理审查委员会 |
||
|
Name of the ethic committee: |
Chinese Center for Disease Control and Prevention Ethical Review Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-05-26 00:00:00 | ||
|
伦理委员会联系人: |
宋渝丹 |
||
|
Contact Name of the ethic committee: |
Song Yudan |
||
|
伦理委员会联系地址: |
北京市昌平区昌百路155号 |
||
|
Contact Address of the ethic committee: |
155 Changbai Road, Changping District, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10-58900243 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国疾病预防控制中心 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Chinese Center for Disease Control and Prevention |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市西城区南纬路27号 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
155 Changbai Road, Changping District, Beijing, China |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金委员会 |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
脑卒中 |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Stroke |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
(1)提出医院-社区-家庭-个体互动式的脑卒中健康管理综合干预模式; (2)设计和开发脑卒中健康管理综合干预APP; (3)通过随机对照试验评价干预效果,为我国脑卒中防控提供新的干预手段。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
1. Propose an integrated intervention model for health management of stroke with hospital-community-family-individual interactions; 2. Design and develop comprehensive intervention APP for stroke health management; 3. Evaluate the effects of intervention model through parallel, and provide a new intervention method for community-based prevention and control of stroke in China. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
(1)患有严重或威胁生命的疾病; |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1. The patients with serious or life-threatening diseases; |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-10-01 00:00:00至 To 2022-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-10-01 00:00:00 至 To 2022-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用多阶段分层整群随机抽样的方式,首先按地域和气候差异分为南方和北方,在南北方各抽取2个省,在每个省抽取符合现场备选和样本量的县区,然后以村和居委会为单位,将人群随机分配到干预组和对照组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study adopts a multi-stage stratified cluster random sampling method. We selected two provinces from the north and the south of China each, then choose eligible counties and districts from each province, and take the village and neighborhood committee as the unit to randomly assign the population. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
受APP 特点影响,本研究只能对统计分析人员做到干预分组设盲。 |
|
Blinding: |
According to the characteristics of this APP,our study can only blind statistical analysts. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
发表文章;按需公开 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Publication; on demand based |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
使用调查问卷记录采集数据;电子采集数据 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |